Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care

References

• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med20071461285786717577005
   PubMed Web of Science ®Google Scholar
• BakerWLCiosDASanderSDColemanCIMeta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United StatesJ Manag Care Pharm200915324425219326955
   PubMed Web of Science ®Google Scholar
• HylekEMEvans-MolinaCSheaCHenaultLEReganSMajor hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillationCirculation2007115212689269617515465
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• HylekEMHeldCAlexanderJHMajor bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesJ Am Coll Cardiol201463202141214724657685
   PubMed Web of Science ®Google Scholar
• Beyer-WestendorfJFörsterKPannachSRates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registryBlood2014124695596224859362
   PubMed Web of Science ®Google Scholar
• MajeedAHwangHGConnollySJManagement and outcomes of major bleeding during treatment with dabigatran or warfarinCirculation2013128212325233224081972
   PubMed Web of Science ®Google Scholar
• HankeyGJStevensSRPicciniJPIntracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationStroke20144551304131224743444
   PubMed Web of Science ®Google Scholar
• HartRGDienerHCYangSIntracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialStroke20124361511151722492518
   PubMed Web of Science ®Google Scholar
• HeldCHylekEMAlexanderJHClinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialEur Heart J201536201264127225499871
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTRostNSCerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48Stroke20144582372237824947287
   PubMed Web of Science ®Google Scholar
• EzekowitzMDWallentinLConnollySJDabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillationCirculation2010122222246225321147728
   PubMed Web of Science ®Google Scholar
• MahaffeyKWWojdylaDHankeyGJClinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialAnn Intern Med20131581286186823778903
   PubMed Web of Science ®Google Scholar
• GarciaDAWallentinLLopesRDApixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trialAm Heart J2013166354955824016506
   PubMed Web of Science ®Google Scholar
• O’DonoghueMLRuffCTGiuglianoRPEdoxaban vs warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Eur Heart J201536231470147725687352
   PubMed Web of Science ®Google Scholar
• WallentinLYusufSEzekowitzMDEfficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLancet2010376974597598320801496
   PubMed Web of Science ®Google Scholar
• PicciniJPHellkampASLokhnyginaYRelationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJ Am Heart Assoc201432e00052124755148
   PubMed Web of Science ®Google Scholar
• WallentinLLopesRDHannaMEfficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillationCirculation2013127222166217623640971
   PubMed Web of Science ®Google Scholar
• HalperinJLHankeyGJWojdylaDMEfficacy and safety of rivaroxaban compared with warfarin among elderly patients with non-valvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Circulation2014130213814624895454
   PubMed Web of Science ®Google Scholar
• HalvorsenSAtarDYangHEfficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trialEur Heart J201435281864187224561548
   PubMed Web of Science ®Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation2011123212363237221576658
   PubMed Web of Science ®Google Scholar
• RosandJEckmanMHKnudsenKASingerDEGreenbergSMThe effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhageArch Intern Med2004164888088415111374
   PubMedGoogle Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar
• DienerHCConnollySJEzekowitzMDDabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialLancet Neurol20109121157116321059484
   PubMed Web of Science ®Google Scholar
• HankeyGJPatelMRStevensSRRivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFLancet Neurol201211431532222402056
   PubMed Web of Science ®Google Scholar
• EastonJDLopesRDBahitMCApixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialLancet Neurol201211650351122572202
   PubMed Web of Science ®Google Scholar
• OldgrenJAlingsMDariusHRisks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trialAnn Intern Med201115510660667W20422084332
   PubMed Web of Science ®Google Scholar
• LopesRDAl-KhatibSMWallentinLEfficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialLancet201238098551749175823036896
   PubMed Web of Science ®Google Scholar
• FoxKAPicciniJPWojdylaDPrevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEur Heart J201132192387239421873708
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaR2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• EikelboomJWConnollySJBrueckmannMDabigatran versus warfarin in patients with mechanical heart valvesN Engl J Med2013369131206121423991661
   PubMed Web of Science ®Google Scholar
• Dabigatran: Pradaxa® (dabigatran) [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals2010
   Google Scholar
• Rivaroxaban: Xarelto® (rivaroxaban) [package insert]Titusville, NJJanssen Pharmaceuticals2011
   Google Scholar
• Apixaban: Eliquis® (apixaban) [package insert]Princeton, NJ, and New York, NYBristol-Myers Squibb, and Pfizer2012
   Google Scholar
• Edoxaban: Savaysa™ (edoxaban) [package insert]Parsippany, NJDaiichi Sankyo2015
   Google Scholar